Dose Insider / Glossary / GLP-1 receptor

GLP-1 receptorWhat it is, where it sits and which medicines act on it

Updated November 20, 2026 · 3 min read · Drucker 2018, Nauck 2021, FDA and DailyMed labels

The GLP-1 receptor is a protein on the surface of certain cells that responds to glucagon-like peptide-1, a hormone released by the gut after eating.

4,113.58Semaglutide, a peptide, size of the molecule
Size of the moleculeMolecular weight, from the labelsExenatide, a peptide4,186.6Semaglutide, a peptide4,113.58Liraglutide, a peptide3,751.2Orforglipron, a small molecule902.0Size of the moleculeMolecular weight, from the labelsExenatide, a peptide4,186.6Semaglutide, a peptide4,113.58Liraglutide, a peptide3,751.2Orforglipron, a small molecule902.0

Both activate the same receptor.

On this page

When GLP-1 binds to it, the receptor sets off effects that raise insulin, lower glucagon, slow the emptying of the stomach and reduce food intake. Every GLP-1 medicine, from exenatide to semaglutide and tirzepatide, works by activating this receptor, which is why the class is called GLP-1 receptor agonists.1,2

The natural hormone and its receptor

GLP-1 is released from enteroendocrine cells in the gut wall. A review by Daniel Drucker describes it as controlling the rise in blood sugar after meals by boosting insulin and holding back glucagon, and as slowing stomach emptying and food intake, actions that help absorb nutrients while limiting weight gain.1

The body's own GLP-1 is short-lived. The Saxenda label puts its half-life at 1.5 to 2 minutes, because two enzymes, DPP-4 and neutral endopeptidase, break it down almost as soon as it is made.3 That is the main problem the medicines solve. Each one activates the same receptor but resists those enzymes and stays in the blood far longer, from 2.4 hours for exenatide to about 1 week for semaglutide.3,4,5

Where the receptors are

The Drucker review traces GLP-1 receptor signals through the islets of the pancreas, where insulin is made, and through pathways involved in appetite, inflammation and the heart.1 The Wegovy label adds that the receptor is present in several areas of the brain involved in appetite regulation, and that in animal studies semaglutide reached and activated neurons in brain regions that regulate food intake.6 The Foundayo label says the same of orforglipron.7 The labels link the weight loss to appetite: they say these medicines decrease calorie intake, likely by acting on appetite.6

What activating the receptor does

A review by Michael Nauck and colleagues lists the effects all GLP-1 receptor agonists share:2

Because the insulin effect depends on glucose being high, the review notes that the medicines carry no built-in risk of low blood sugar on their own.2 The labels still warn about low blood sugar when they are combined with insulin or a sulfonylurea.4 The same review notes that the effect on stomach emptying fades over time with the long-acting medicines.2

Medicines that act on the receptor

MoleculeBrandsActs on
ExenatideByettaGLP-1 receptor
LiraglutideVictoza, SaxendaGLP-1 receptor
DulaglutideTrulicityGLP-1 receptor
SemaglutideOzempic, Wegovy, RybelsusGLP-1 receptor
OrforglipronFoundayoGLP-1 receptor
TirzepatideMounjaro, ZepboundGLP-1 and GIP receptors

Section 12.1 of each label.3,4,5,6,7,8

Most of them are peptides, chains of amino acids modeled on GLP-1 or, for exenatide, on a peptide first found in a lizard. Orforglipron is built differently: a much smaller molecule, with a molecular weight of 902.0 against semaglutide's 4,113.58, that still activates the receptor and can be taken as a daily tablet without fasting.7,4 The labels of two older peptides give similar sizes: 4,186.6 for exenatide and 3,751.2 for liraglutide.5,3 Tirzepatide adds the receptor for a second gut hormone, GIP.8

The same receptor, the same side effects

Because they share a target, the medicines share their most common side effects: nausea, vomiting, diarrhea and constipation. Slower stomach emptying is one reason, and the labels warn that it may affect the absorption of pills taken by mouth and matters before anesthesia.6,8 Our page on nausea on a GLP-1 covers what helps.

Sources

  1. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018;27:740-756. doi:10.1016/j.cmet.2018.03.001
  2. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab 2021;46:101102. doi:10.1016/j.molmet.2020.101102
  3. SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published June 15, 2026; sections 12.1 and 12.3. dailymed.nlm.nih.gov
  4. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 5, 11, 12.1 and 12.3. accessdata.fda.gov
  5. BYETTA (exenatide) injection prescribing information. AstraZeneca; DailyMed, version published September 8, 2025; sections 11 and 12. dailymed.nlm.nih.gov
  6. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 5, 6.1 and 12. accessdata.fda.gov
  7. FOUNDAYO (orforglipron) tablets prescribing information. Eli Lilly and Company; DailyMed, version published August 13, 2026; sections 11 and 12. dailymed.nlm.nih.gov
  8. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 7.2 and 12.1. accessdata.fda.gov

Related analyses

Log each dose and see how your symptoms and appetite follow it.

Open Dose Insider